ID   BONNA-12
AC   CVCL_1090
SY   Bonna-12; BONNA12; Bonna12
DR   CLO; CLO_0002014
DR   CLDB; cl473
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473418
DR   CCLE; BONNA12_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM00984
DR   Cosmic; 906695
DR   Cosmic; 2690006
DR   Cosmic-CLP; 906695
DR   DepMap; ACH-001452
DR   DSMZ; ACC-150
DR   GEO; GSM1669627
DR   Wikidata; Q54797948
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1313127;
RX   PubMed=20164919;
RX   PubMed=20454443;
RX   PubMed=22653958;
RX   PubMed=27397505;
RX   PubMed=27463354;
RX   PubMed=30894373;
RX   PubMed=31160637;
CC   Problematic cell line: Possibly misidentified. It is not certain that this cell line originate from a hairy cell leukemia (PubMed=22653958).
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Characteristics: Has lost chromosome Y.
CC   Doubling time: ~50-60 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.35%; Native American=0%; East Asian, North=1.04%; East Asian, South=0%; South Asian=0%; European, North=71.7%; European, South=26.91% (PubMed=30894373).
CC   Derived from sampling site: Spleen.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 12 (Cosmic-CLP)
ST   D16S539: 11,12 (DSMZ)
ST   D5S818: 9,14
ST   D7S820: 8,10
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C7402; Hairy cell leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 18
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1313127;
RA   Kluin-Nelemans H.C., Wientjens G.-J.H.M., Jansen J.H.;
RT   "Establishment of a new human B-cell line (BONNA-12) with trisomy 9
RT   and trisomy 12 chromosomal abnormality.";
RL   Leukemia 6:158-158(1992).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767-904767(2010).
//
RX   PubMed=22653958; DOI=10.1182/blood-2011-12-400374;
RA   Tiacci E., Pucciarini A., Bigerna B., Pettirossi V., Strozzini F.,
RA   Martelli M.P., Tabarrini A., Drexler H.G., Falini B.;
RT   "Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M,
RT   and HC-1 questions their origin from hairy cell leukemia.";
RL   Blood 119:5332-5333(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27463354; DOI=10.3109/10428199109067637;
RA   Wientjens G.-J.H.M., Jansen J.H., Wessels H.W., Kibbelaar R.E.,
RA   Beverstock G.C., Brederoo P., Kluin-Nelemans H.C.;
RT   "Characterization of a new human B cell line (Bonna-12) with trisomy 9
RT   and trisomy 12 chromosomal abnormality.";
RL   Leuk. Lymphoma 5:415-422(1991).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//